Cellanyx | 583 followers on LinkedIn. About: Cellanyx is developing proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and inform clinical decision making. The Company’s initial tests, for prostate cancer and Stage 0 breast cancer, both of which have demonstrated clinical proof of concept, are being developed to augment traditional pathology tests. Technology: Cellanyx’s technology analyzes multiple molecular, cellular and biophysical phenotypic markers of individual living cells and their behavior including protein dynamics and cell motility.